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ABSTRACT
Compounds containg catechol or bisphosphonate were tested as inhibitors of the zinc metalloproteases,
thermolysin (TLN), pseudolysin (PLN) and aureolysin (ALN) which are bacterial virulence factors, and the
human matrix metalloproteases MMP-9 and 14. Inhibition of virulence is a putative strategy in the devel-
opment of antibacterial drugs, but the inhibitors should not interfere with human enzymes. Docking indi-
cated that the inhibitors bound MMP-9 and MMP-14 with the phenyl, biphenyl, chlorophenyl, nitrophenyl
or methoxyphenyl ringsystem in the S10-subpocket, while these ringsystems entered the S20- or S1 -sub-
pockets or a region involving amino acids in the S10- and S20-subpockets of the bacterial enzymes. An
arginine conserved among the bacterial enzymes seemed to hinder entrance deeply into the S10-sub-
pocket. Only the bisphosphonate containing compound RC2 bound stronger to PLN and TLN than to
MMP-9 and MMP-14. Docking indicated that the reason was that the conserved arginine (R203 in TLN and
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It is estimated that there are more than 60000 different pro-
teases1,2. In vertebrates they are involved in regulation of physio-
logic processes such as cell growth, angiogenesis, blood pressure,
coagulation, cell signalling, reproduction, wound repair, hemosta-
sis and homeostasis2–7. Proteases are either secreted from cells or
localised inside cells. They are divided into classes and clans
depending on the active site residues taking part in the catalytic
reaction (Merops database)8–10. The major classes found in all
organisms are aspartate-, threonine-, cysteine-, serine- and met-
allo-proteases, but in addition the classes glutamate-, aspargine-
and mixed-proteases have been detected in microorganisms
(Merops database)10.
Dysregulation of one or several proteases in humans is often
associated with disease3,4,11–14 and several proteases are potential
targets for therapeutic interventions15–18. In humans there are
around 570 different proteases and approximately 190 of these
are metalloproteases19. Of around 280 cell-secreted human pro-
teases, approximately 120 are metalloproteases2,19,20. Matrixins or
matrix metalloproteases (MMPs) is a family of secreted and mem-
brane associated calcium dependent metalloproteases which con-
tains a catalytic and a structural zinc ion11. MMPs belong to the
M10 family of proteases. In humans there are 23 different MMPs,
and MMP-9 and -14 are two of the members11. One or several
members of the MMP family are overexpressed and functionally
involved in pathological conditions such as chronic venous dis-
ease, fibrotic disorders, inflammation, liver diseases, lung diseases,
neurological diseases, osteoarthritis, viral infection, cardiovascular
diseases and in various cancer forms21. Several investigators both
in academia and industry have developed MMP inhibitors
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interacting with the active site. However, in clinical tests the vast
majority of MMP inhibitors have failed22 The most likely reason is
that the MMPs are of major importance in many physiological
processes such as cell apoptosis, embryogenesis, immune
response, morphogenesis, tissue remodelling, tooth enamel forma-
tion, reproduction, menstruation, wound healing, angiogenesis
and axonal growth13,21,23. MMPs are tightly regulated and
expressed in all human tissues and organs13,22,23, and therefore an
uncontrolled activity regulation of one or several MMPs by an
inhibitor should be avoided. In microorganisms, proteases are
involved in processes such as generation of nutrition, growth, sur-
vival and invasion into host organisms24–30. Bacterial infectious
diseases claim millions of casualties each year, and the spreading
of antibiotic multi-resistance among central human pathogenic
bacteria is recognised as a major global health concern and a
pressing societal challenge. Development of new antibiotics with
novel modes of action and innovative strategies to efficiently fight
bacterial infections are urgently needed. Inhibition of bacterial
virulence rather than directly targeting bacterial growth and via-
bility has gained increasing interests in anti-infective drug discov-
ery31,32. Such compounds may impose less evolutional pressure
for resistance development than classical antibiotics, and have lim-
ited impact on the host commensal flora. Several proteases are
bacterial virulent factors and therapeutically interesting as putative
antibacterial drug targets26–29,33. However, compounds targeting
bacterial virulence have so far not been approved as drugs34,35.
MMP-9 (gelatinase B) is secreted, while MMP-14 belongs to the
membrane type metalloproteases (MT-MMPs), and is also called
membrane type 1 metalloprotease (MT1-MMP). The MT-MMPs
contain either a transmembrane domain or a GPI-membrane
anchor, with the catalytic site located outside the cell in the extra-
cellular environment11. The MMPs are constituted of different
structural domains, and both MMP-9 and MMP-14 contain an N-
terminal prodomain, followed by a catalytic domain, a hinge
region and a C-terminal hemopexin like (HPX) domain. In MMP-14,
the HPX domain is followed by the transmembrane domain, while
MMP-9 contains three fibronectin-II like (FnII) repeats in the cata-
lytic domain11. The MMPs belong to the clan metzincins and the
catalytic zinc ion is bound to the protein through three histidines
of the segment (HEXXHXXGXXH/DþM)8,9. The fourth zinc ligand
in the inactive proform is the cysteine in the PRCGV motif of the
pro-domain36,37. The fourth zinc ligand in the activated MMPs is a
water molecule, that also binds to the side chain of the glutamate
that follows the first histidine in the zinc binding segment8,9.
MMP-9 can be activated in the extracellular environment by natur-
ally occurring proteases such as trypsin, kallikrein, MMP-2 and
MMP-3, but also by mercurial and organomercurial compounds
such as HgCl2 and APMA (p-aminophenylmercuric acetate) and
bacterial metalloproteases such as thermolysin (TLN) and pseudo-
lysin (PLN)37. MMP-14, like the other MT-MMPs, are activated
inside cells by the serine protease furin11. MMP-14 is the most
studied enzyme among membrane-linked MMPs, while MMP-9
(gelatinase B) is the most studied among secreted MMPs14,38.
Binding of inhibitors to the active site of MMP-14 and MMP-9
have been extensively studied both by kinetic and X-ray crystal-
lography39–47. The active sites of the MMPs are similar but not
identical. Their S1’-subpocket determines the substrate cleavage
site, and they all prefer hydrophobic amino acids in
this pocket48,49.
TLN from Bacillus thermoproteolyticus is the model enzyme of
the M4 family of proteases, which is also termed the thermolysin
family50. These enzymes have a zinc ion in the catalytic site, which
has tetrahedral coordination. Two histidines of a HEXXH motif and
a glutamic acid located 18–72 residues C-terminal to the HEXXH
motif are the three ligands that anchor the zinc ion to the
enzyme, while the fourth ligand is a water molecule as in the
MMPs, which also binds the side chain of the glutamate following
the first histidine in the zinc binding segment8,9,50. Inhibitors con-
taining a metal binding group replace the catalytic water mol-
ecule on the zinc ion when they bind the catalytic site51. TLN, PLN
from Pseudomonas aeruginosa (LasB or elastase of P. aeruginosa)
and aureolysin (ALN) from Staphylococcus aureus belong to the
subclan MA(E) of the M4 family, also known as the “Glu-
zincins”8,9,50. These three proteases have several similarities des-
pite a modest sequence identity (28% between TLN and PLN)52,53.
The three dimensional (3D) structures of PLN and TLN have been
extensively studied, also in complex with inhibitors, and reveal
large similarities in the overall structure. The main structural differ-
ences are that PLN consists of a slightly more open substrate
binding cleft than TLN, and that PLN has one structural calcium
while TLN has three53–55. For ALN only the 3D-structure of the
free enzyme is known56. Although PLN is not as well characterised
as TLN, it appears that the slight difference in substrate specificity
between the two enzymes is mainly due to the size of the S10-sub-
pocket and a more open substrate binding cleft in PLN than in
TLN. PLN has a broader substrate specificity than most other M4
family members including TLN, although all these enzymes prefer
a hydrophobic amino acid at the P1’ position. Furthermore, for
substrate degradation four subsites of PLN require to be
occupied50,53,55.
PLN, TLN and ALN are secreted bacterial virulence factors, and
inhibitors may be new antibacterial drugs, either alone or used as
adjuvant to traditional antibacterial treatment. PLN, TLN and ALN
have structural resemblance with human MMPs. In order to have
a therapeutic value, compounds targeting these virulence factors
should not interfere strongly with the function of human MMPs,
due to the importance of MMPs in physiological processes.
Identifying structural determinants for strong binding to the bac-
terial M4 proteases and human MMPs would therefore be of piv-
otal importance for the development of new antibacterial drugs.
In this study, we have studied several catechol containing and
bisphosphonate containing compounds for their inhibition of TLN,
PLN, ALN, MMP-9 and MMP-14 in order to identify new M4 inhibi-
tors and investigate structural determinants that might be import-
ant for selective binding using inhibition kinetic and
molecular modelling.
Results and discussion
Km values for the fluorescence quenched substrates
At conditions used in the present work (1% DMSO in all assays),
the Km values of the substrate McaPLGL(Dpa)AR-NH2 with APMA-
activated recombinant MMP-9 (rMMP-9(A)), trypsin-activated
MMP-9 from THP-1 cells (MMP-9(T)) and MMP-14 were 4 ± 1, 6 ± 2
and 4.9 ± 0.4 mM, while the Km values of the substrate
McaRPPGFSAFK(Dnp)-OH with ALN, PLN and TLN were 76 ± 7,
24 ± 8 and 6± 1 mM, respectively. The estimated Km values for ALN
and PLN must be regarded as uncertain since the highest sub-
strate concentration used was 10mM due to quenching. The
obtained Km values are very similar to those previously obtained
for theses enzymes without DMSO57 or with a DMSO concentra-
tion of 5%58. Previously it was reported that TLN is inactivated in
most organic cosolvents, but can tolerate up to 10% DMSO to
enhance substrate solubility59. For TLN, the Km value was also
determined with a DMSO concentration of 2%. This resulted in a
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Km value of 7 ± 1 lM which is not significantly different from the
value obtained in the presence of 1% DMSO.
Quenching experiments with catechol containing compounds
and bisphosphonates
All compounds were first tested for possible quenching of the
formed fluorescence product. The experiments were performed
with varying concentrations of the putative inhibitors (0 100 lM)
against varying fluorescence product (McaPL-OH) concentration as
previously described for PAC-1 and Isatin derivatives58, and as
described in the experimental section. These experiments revealed
that in contrast to the PAC-1 and Isatin derivatives58, neither the
catechol derivatives nor the bisphosphonates used in the present
work quenched the fluorescence product. However, some of the
compounds showed fluorescence at the emission and excitation
wavelength used, but that did not affect the inhibitory assays as
enzymatic reactions were followed continuously.
Inhibitory effects of catechol containing compounds
The inhibitorial power of 100 lM of the eight catechol containing
compounds was tested against the two human metalloproteases
MMP-9(T) and MMP-14 and the three bacterial metalloproteases
ALN, PLN and TLN (Figure 1). In order to detect putative slow and
slow-tight binding, the catechol derivatives were first incubated
along with the enzyme for 15min at 37 C. In controls without
inhibitor present, enzymes and buffer were preincubated under
identical conditions. Thereafter, the enzyme reaction was started
by adding the relevant chromogenic substrate and the rate was
followed continuously for 30min. Except for BF486, which did not
affect MMP-9, and BF482 which did not affect PLN, all cathecol
containg compounds showed inhibition of the five proteases
(Figure 1). Both BF471 and BF489 showed more than 50% inhib-
ition of all five proteases, while ML32 reduced the activity more
than 50% for four of the proteases (not for TLN). The activity was
reduced with more than 50%, by MT336 for the two MMPs, by
BF482 for MMP-9(T) and by ML33 for ALN (Figure 1). In all other
inhibitory studies with catechol containing compounds, the activ-
ity was reduced between 0 and 45%.
X-ray crystallography studies showed that BF471 binds to the
active site of MMP-860, and hence we could expect that all tested
catechol derivatives should bind the active site. To assure that this
is correct, the inhibitors BF471 and BF489 were tested against
varying McaRPPGFSAFK(Dnp)-OH using TLN as described in the
Experimental section. The results showed that the two catechol
derivatives competed with the substrate (data not shown) and the
Ki values obtained were 57± 6 lM for BF471 and 73± 11lM for
BF489. It should be noted that the reaction was started by adding
the enzyme to the substrate-inhibitor mixtures. In the case of slow
binding, the full potential of these inhibitors would not be real-
ised by this inhibitory assay. When the activity was reduced by
more than 60%, experiments were performed with varying con-
centrations of the catechol derivatives. IC50 values were obtained
from dose response plots, and Ki values were determined from
the IC50 values based on substrate competitive inhibition. By the
use of Ki values, we can compare the binding strength of the
compounds for the different enzymes and not only comparing the
compounds ability to bind one enzyme. The obtained Ki values of
the catechol contaning compounds for the five tested proteases
are given in Table 1. There are several possible explanations for
vi/v0
































































Figure 1. Inhibitory effect of 100lM of the catechol containing compounds on the activity of the human metalloproteases, MMP-9 and MMP-14, and the bacterial
metalloproteases TLN, PLN and ALN. The inhibition experiments were performed by using a fixed concentration of 4lM of both the MMP-9 and MMP-14 substrate
McaPLGL(Dpa)AR-NH2 and the ALN, PLN and TLN substrate McaRPPGFSAFK(Dnp)-OH. The vi/v0 (mean± sd) were based on 4–6 experiments.
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the deviation in determined Ki value of BF471 and BF489 for TLN
from the dose response plots and the double inverse plots. One
possible explanation is that the catechol compounds are slow
binders, and hence less inhibitory activity is observed without pre-
incubation of enzyme and inhibitor.
Figure 1 and Table 1 show that the position of the OH-groups
in the catechol moiety affects the binding. Moving the OH-group
from position 2 to position 4 (ML32 vs. BF471 and ML33 vs.
BF489) largely strengthen the binding for four of the enzymes,
while the effect was less for ALN. Another striking effect occurs
with the addition of a methylene group between the catechol
moiety and the sulphonamide group, which resulted in weaker
binding (BF489 vs. BF486 and ML32 vs. BF466). Changing the
sulphonyl group to a methylene group and the methylene
between the catechol moiety and the sulphonylamide moiety to a
carbonyl (BF466 vs. MT336) resulted in stronger binding for the
two MMPs, but with only limited activity changes for the bacterial
enzymes. Overall, it appeared that the structural differences
between the catechol derivatives had little effect on the ALN
activity, while the activity of the other four enzymes varied corres-
pondingly. None of the catechol derivatives showed stronger
binding to the bacterial than the human enzymes. The largest dif-
ferences in binding strengths between the human MMPs and the
bacterial proteases were seen for MT336.
Except for ML33, all catechol derivatives have previously been
tested for binding to MMP-2, MMP-8 and MMP-960. For six of
them, IC50 values for the enzymes between 2 and 12 mM were
reported. The exception was MT336, which had IC50 values
between 4 and 56 mM. The Ki values for MMP-9 in the present
study were higher than the IC50 values in the previous study, the
exception was MT336 for which we obtained a lower value. It is
not easy to point out a single factor in the experiments contribu-
ting to deviations between the studies. Both studies used a pH of
7.5 but the buffer compositions were slightly different. In the pre-
sent study, we used MMP-9 purified from THP-1 cells and acti-
vated by trypsin, and hence the enzyme has its C-terminal
hemopexin domain intact57. Tauro et al.60 used a commercial
active MMP-9 produced in E-coli that only contained the catalytic
domain and the fibronectin-like (FnII) module. We do not believe
that the use of the two different variants of MMP-9 should affect
binding of the catechol derivatives, as we previously have shown
that small MMP inhibitors, like galardin and an azasugar-based
hydroxamate compound had, the same strength of binding to dif-
ferent N- and C-terminal truncated variants of recombinant MMP-
9 and trypsin activated MMP-9 from THP-1 cells57. A factor that
may contribute to differences is that after preincubation of MMP-9
with catechol derivatives and adding of the substrate for starting
the reaction, we followed the reaction continuously for 30min,
while Tauro et al.60 used an endpoint assay allowing the reaction
to proceed for 2 to 4 h before the fluorescence was measured. We
did some tests to determine if some of these differences could
affect the binding results. In the test experiments, we used rMMP-
9(A) which differs from the MMP-9(T) by a slightly different N-ter-
minal and a largely truncated C-terminal HPX domain57. One hun-
dred mM of BF466 was tested where the 0.1M Hepes buffer pH
7.5 was exchanged to a 0.1M Tris-HCl buffer pH 7.5. The rMMP-
9(A) was preincubated with BF466 for 0, 15 and 30min at 37 C
and the reaction was started by the addition of the substrate
McaPLGL(Dpa)AR-NH2 (4 mM in the assay) following the reaction
continuously for 3 h. The controls without BF466 were treated
identically. The obtained vi/v0 values for the three time points
were 0.74 ± 0.04 (N¼ 4), 0.68 ± 0.02 (N¼ 4) and 0.73 ± 0.05 (N¼ 4).
These results fit well with obtained data for MMP-9(T) in Hepes
buffer (Figure 1) suggesting that neither the buffer nor the origin
of the MMP-9 affected the binding of this inhibitor. Further, the
compound could not be regarded as a slow binder of MMP-9. We
also tested if the use of an end point assay could affect the
results. Here rMMP-9(A) was preincubated with different concen-
trations of BF482 for 30min in 0.1M Hepes pH 7.5 and the reac-
tion was started by the addition of McaPLGL(Dpa)AR-NH2 (4 mM in
the assay). The reaction was allowed to proceed for 4 h, and the
reaction was stopped by addition of EDTA (end concentration
10mM) and the relative fluorescence intensity determined. This
resulted in an IC50 value of 40 ± 1 mM and a Ki value of
20.1 ± 0.7 mM (Figure 2), while the vi/v0 value for 100 mM inhibitor
was similar to that in Figure 1. This suggests that the use of either
initial rate assays or end point assays is not a reason for the
obtained differences between this study and that of Tauro et al.60.
Docking
Docking of the catechol containing compounds into the X-ray
structure of MMP-9 (PDB ID: 5cuh) and MMP-14 (PDB ID: 1bqq)
showed that the biphenyl, bromophenyl and methoxyphenyl
group of the compounds enter the S1’ -subpocket. The interaction
modes of BF471 in MMP-9 and MMP-14 were very similar to that
observed in the X-ray structure of BF471 with MMP-860. In
Figure 2. Dose response plot of BF482 for MMP-9(A). The enzyme with and with-
out inhibitor was pre-incubated for 30min at room temperature and the reaction
was started by adding McaPLGL(Dpa)AR-NH2 (4lM in assay). The reaction was
allowed to proceed for 4 h at 37 C and stopped by the addition of EDTA (10mM
end concentration). The relative fluorescence was determined with the Clariostar
plate reader as described in the Experimental Section, where vi and v0 are the
reaction rates in the presence and absence of BF482, respectively. Each point on
the curve shows the mean± sd (N¼ 5 for all points except for two points where
N¼ 4). The regression coefficient r2 is 0.97, with a determined IC50 value of
38.8 ± 0.9lM and a Ki value of 19.4 ± 0.4lM.
Table 1. Ki values of the catechol containing compounds for TLN, PLN, ALN,
MMP-14, and MMP-9(T).
Compound
Ki ± sd (lM)
McaRPPGFSAFK(Dnp)-OH McaPLGL(Dpa)AR-NH2
TLN PLN ALN MMP-14 MMP-9(T)
ML32 N.D. 38 ± 8 N.D. 19 ± 0.8 51 ± 17
BF471 13 ± 2 9± 3 49 ± 5 6.6 ± 0. 6 13 ± 2
BF489 14 ± 5 16 ± 3 N.D. 8.3 ± 0.6 12.6 ± 0.6
MT336 N.D. N.D. N.D. 12 ± 1 13 ± 1
Ki values determined for both bacterial and human metalloproteases using two
different fluorescence quenched peptide substrates, McaRPPGFSAFK(Dnp)-OH
(for TLN, PLN, and ALN) and McaPLGL(Dpa)AR-NH2 (for MMP-9(T) and MMP-14).
The concentration of the substrates used was 4 mM and the highest concentra-
tion of tested inhibitors was 100 mM. Compounds included are only those where
100 mM of the compound reduced the enzymatic activity by 60% or more as
described in the text. The Ki values are based on 4–6 experiments.
N.D.: not determined.
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contrast, docking catechol containing compounds into TLN (PDB
ID: 5dpe) and PLN (PDB ID: 1u4g) showed docking poses both
with the diphenyl, bromophenyl and methoxyphenyl groups
entering the S1- or the S10/S20 -subpockets. The cathecol contain-
ing compounds bind quite weak to ALN, and docking indicated
binding modes quite different from the other proteases (Figure 3).
It seems like the side chain of R203 in TLN, corresponding to R200
in ALN and R197 in PLN, is the main reason for the binding pose
differences between the human and bacterial proteases. For most
of the compounds, the arginine side chain orientation hinders the
biphenyl, bromophenyl and methoxyphenyl groups of the com-
pounds to enter deeply into the S1’-subpocket (Figure 3). This
arginine is known as functionally important for TLN-like proteases,
and is suggested to interact with a backbone carbonyl group of
the substrates61 and is located at the border between the S10- and
S20-subpockets. Table 2 shows the most important amino acids in
the different protease subpockets for binding the compounds in
the present study.
The highest scored pose of BF471 with TLN was with the
diphenyl moiety into the S20-subpocket, with the sulphonamide
group interacting between the side chain of R203, the side chain
of N112 in the S2’-subpocket and H231 (Figure 3). Both hydroxyl
groups of the BF471 catechol ring interacted with the Zn atom,
while the hydroxyl group in position 3 also created a hydrogen
bond with E143. However, the best pose of BF489 in TLN had the
bromophenyl entirely into the S10-subpocket, while a hydroxyl of
the catechol ring interacted with the backbone of W115 (S1-sub-
pocket) and the amide with E143, thereby obtaining a binding
pose quite similar to that observed for BF471 and the other cat-
echol containing compounds in MMP-9 and MMP-14 (Figure 3).
The highest scored pose of BF471 in PLN was with the
diphenyl moiety into the S1-subpocket interacting close to Y155,
while the catechol moiety entered into the region between the
S10- and S20-subpocket with the hydroxyl groups interacting with
R198 (Figure 3). The NH-group formed a hydrogen bond with
E141. Moving the hydroxyl group from position 2 (ML32) to pos-
ition 4 (BF471) of the catechol moiety resulted in increased bind-
ing affinity towards all enzymes. In PLN the change allowed
interactions between both hydroxyl groups of BF471 and R198,
while only one hydroxyl group of ML32 interacted with R198
which may explain the higher PLN affinity of BF471 than of ML32.
The compounds showed weak affinity for ALN (Figure 1), and
only BF471 reduced the enzymatic activity with more than 60% at
a concentration of 100 mM and a Ki value of 49lM was deter-
mined. BF471 obtained a docking pose in ALN quite different

















































Figure 3. BF471 docked into PLN, TLN, ALN and MMP-9, and ML32 docked into ALN and MMP-9. Zinc is shown in dark grey. The side chain of zinc coordinating
amino acids are shown in blue. The side chains of some amino acids of importance for ligand binding are displayed with the following colour coding of atoms: oxy-
gen: red; nitrogen: blue, carbon: yellow, hydrogen: grey. Colour coding of ligand atoms: oxygen: red; sulphur: green; nitrogen: blue; hydrogen; grey; carbon (BF471):
pink; carbon (ML32): orange.
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groups formed hydrogen bonds with Q152 and N167 in the S1-
subpocket, while the NH group formed hydrogen bonds with the
backbone of W117 and with the biphenyl ring-system located
above the Zn2þand R200. The possibility of two hydrogen bonds
(with Q152 and N167) is perturbed for ML32 with the hydroxyl
group in position 2 (Figure 3). Instead the hydroxyl groups of
ML32 were occupied with Zn2þ, while diphenyl ring system was
highly exposed to solvent without clear interactions with amino
acids in ALN. Based on the docking it was not easy to explain the
increased binding affinity of BF471 for ALN compared with ML32.
Both compounds docked quite similar into the enzyme. However,
the meta-hydroxyl group (position 3) of ML32 was located further
from Y157 in the S1-subpocket without the possibility of a hydro-
gen bond, and in addition the sulphonamide group in ML32 was
located further from H231 than the corresponding group
in BF471.
Docking indicated that ML32 and ML33 bound similarly to
MMP-9 and -14. The hydroxyl group in position 2 of both com-
pounds formed hydrogen bonds with the two oxygen atoms of
the side chain carboxyl group of E402 (MMP-9 numbering). The
hydroxyl group in position 2 seems to replace the zinc-bound
water in the free enzyme, as it also interacted with the catalytic
zinc. The two oxygen atoms at the sulphonylamide group formed
hydrogen bonds with the main chain NH groups of L187 and
A189, while the amide hydrogen of the compounds formed
hydrogen bonds with the main chain carbonyl of P421. Thus the
main difference in binding strength between ML32 and ML33 for
MMP-9 and -14 is mainly attributed to the difference in interaction
with the S1’-subpocket by the diphenyl and the methoxy-
phenyl group.
The position of the OH– groups in the catechol in relation to
the position of the amide nitrogen bound to the catechol seemed
important for inhibitory capacity of the compounds. Moving the
hydroxyl in position 2 of ML32 and ML33 into position 4 (BF471
and BF489) seemed to strengthen binding to MMP-9 and MMP-14
(Table 1, Figure 1). BF471 docked into MMP-9 with the hydroxyl
group in position 3 forming a hydrogen bond with the side chain
of E402, while the hydroxyl group in postion 4 interacted with the
backbone CO of A191. Both hydroxyl groups of BF471 and BF489
also interacted with Zn2þ, while only the hydroxyl group in pos-
ition 2 of ML32 and ML33 interacted with Zn2þ. Introduction of a
methyl group between sulphonylamide moiety and the catechol
ring of BF489 giving compound BF486 resulted in decreased
inhibition of all enzymes (Figure 1). Docking indicated that the
bromophenyl group of BF486 was deeper into the S1’-subpocket
of MMP-9 and -14 than that of BF489, and one of the oxygen at
the sulphonylamide group formed a hydrogen bond with the
main chain nitrogen of Y423 and not with A189 and L188 as seen
for BF489. Furthermore, one side chain carbonyl oxygen of E402
formed a hydrogen bond with the NH group of the sulphonyla-
mide moiety of BF486, while the other E402 carbonyl oxygen
interacted with the hydroxyl group in positon 3 of the catechol. In
addition, the position 3 hydroxyl group interacted with the back-
bone CO of A191. These overall changes result in weaker binding
of BF486 than of BF489.
MT336 differs from BF466 in that the sulphonyl group of BF466
is replaced by a methylene group, and the methyl group between
the sulphonylamide moiety and the catechol ring by a carbonyl
group. Hence MT336 contains an amide bond, which improved
the binding for MMP-9 and MMP-14 compared to BF466, but not
for the bacterial enzymes (Figure 1 and Table 1). Docking into
MMP-9 and MMP-14 showed that the carbonyl of MT336 was
much closer to the catalytic zinc atom than any of the oxygen
atoms of the sulphonylamide moiety of BF466, and in addition,
the hydroxyl group in position 2 of the catechol was also closer
to Zn2þ.
Inhibitory effects of bisphosphonates
Figure 4 shows the inhibition of 100 lM of the seven bisphospho-
nates. Replacing the catechol moiety of ML32 and BF471 with a
bisphosphonate giving MT242, and the catechol moiety of ML33
giving LS4, had either no effect or reduced the binding (Figures 1
and 4). Adding a methoxy group to position 4 of the phenyl
group (RC14 to LS4) had almost no effect of the binding, except
for PLN where the binding was strengthened. The addition of a
strong electron withdrawing group (NO2) at the position 4 of the
phenyl group, giving RC2 resulted in a much stronger binding to
PLN and TLN than to the two MMPs (Figure 4 and Table 3).
However, for ALN the binding strength was almost similar to that
without the NO2 group (RC14) or with a methoxy group at the
phenyl ring (LS4) (Figure 4). The binding of RC2 to ALN was even
weaker than for the two human MMPs (Figure 4). Removal of the
sulphonyl group from the bisphosphonate of RC14 giving GD16
had limited effect on the binding of the five proteases (Figure 4).
Addition of a chloride ion at position 4 of the phenyl group of
GD16 giving ML45 resulted in enhanced binding to all proteases
except for TLN (Figure 4 and Table 3). Addition of an additional
phenyl ring to position 4 of the phenyl group of GD16, giving
MT363, gave much stronger binding for four of the proteases.
However, the binding was reduced for ALN (Figure 4 and Table 3).
Most bisphosphonates bound weaker to ALN than to the
other proteases.
The seven bisphosphonate compounds were also previously
tested against various MMPs including MMP-9 and MMP-1462,63.
As for the catechol derivatives, the results for some of the
Table 2. Functionally important amino and amino acids in the S1-, S10- and S20-subpockets of TLN, PLN, ALN, MMP-9, and MMP-14 contributing to the binding of cat-
echol or bisphosphonate containing compounds tested in the present study.
TLN PLN ALN MMP-9 MMP-14
S1-subpocket W115, Y157 W115, Y155 W117, Q152, N167 H190, P193 F204





S20-subpocket N111, F130, Y193, L202 E111, F129, L197 N114, F132, L199 G186, L187, Y218 L235, V236, Y261, Q262







N112, Y114, R200, H228 A189, H190, A191 A200, H201
Zn2þ ligated H142, H146, E166 H140, H144, E164 H144, H148, E168 H401, H405, H411 H239, H243, H248
The subpocket amino acids of MMP-9 in the table are based on the X-ray structure of the inactive MMP-9 mutant E402A lacking the pro, FnII, hinge and HPX
domains bound to a chromogenic substrate (PDB id: 4JIJ)71, while the numbering is as in the PDB id: 1l6j, which includes the three FnII-like repeats in the catalytic
site72. The subpocket amino acids of TLN are based on Krimmer et al.73. Subpocket amino acids of the other enzymes are based on structural superimposition with
TLN (PLN and ALN) and MMP-9 (MMP-14).
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compounds varied slightly from the present results for MMP-9 and
MMP-14. A difference between the assays was that in the present
study we used a preincubation time of 15min at 37 C, while
Rubino et al. 201162 and Tauro et al. 201363 used 30min at 25 C.
Another important difference was that in the present work we fol-
lowed the reaction continuously for 30min after preincubation,
while Rubino et al. 201162 and Tauro et al. 201363 used an end
point assay where the reaction was stopped by adding 3% of
acetic acid after 2–4 h of incubation, followed by fluorescence
measurements. These differences in assay conditions are not likely
explanations for the small differences in the obtained binding val-
ues as previously discussed for the catechol derivatives.
Docking
Docking indicated that like the catechol containg compounds, the
bisphosphonates bind MMP-9 and MMP-14 with the phenyl,
biphenyl, chlorophenyl, nitrophenyl or methoxyphenyl ringsystem
into the S10-subpocket (Figure 5). The phosphate and sulphona-
mide groups were located in the region of Zn2þ, E402, A189,
L187, L188, and V398 (MMP-9 numbering). However, docking into
TLN and PLN was not conclusive, and docking poses with these
ringsystems into the S1- or S10/S20-subpockets of TLN and PLN
were observed for most of the compounds. Notable features from
the binding studies were that RC2 inhibits TLN and PLN stronger
than ALN and the two human MMPs, while MT363 is a decent
inhibitor of all enzymes, except ALN (Figure 4, Table 3).
Docking of RC2 into PLN showed that one of the phosphate
groups interacted with Zn2þ, H223 and E141, while the other phos-
phate group interacted with R198 (two hydrogen bonds) and H223.
The NH-group interacted with the backbone of A113. The NO2-group
was located within the S10-subpocket close to the side chain R198, the
backbone NH-group of G187 and the side chain of the zinc-coordinat-
ing H140 (Figure 5). However, docking poses in PLN with the nitro-
phenyl group of RC2 in the S1-subpocket were also observed. In TLN,
poses quite similar to that described in PLN were observed, but the
highest scored was with the nitrophenyl group into the S1-subpocket
interacting with Y157 and with the nitro group exposed to solvent.
The sulphonamide group interacted with N112 and H231. One of the
phosphate groups interacted with Zn2þ, and the side chains of R203
vi/v0
































































Figure 4. Inhibitory effect of 100lM bisphosphonate containing compounds on the activity of the human metalloproteases, MMP-9 and MMP-14, and the bacterial
metalloproteases TLN, PLN, and ALN. The inhibition experiments were performed by using a fixed concentration of 4lM of both the MMP-9 and MMP-14 substrate
McaPLGL(Dpa)AR-NH2 and the ALN, PLN and TLN substrate McaRPPGFSAFK(Dnp)-OH. The vi/v0 (mean± sd) were based on 4–6 experiments.
Table 3. The obtained Ki values of the various bisphosphonate containing com-
pounds for TLN, PLN, ALN, MMP-14 and MMP-9.
Compounds
Ki ± sd (mM)
McaRPPGFSAFK(Dnp) McaPLGL(Dpa)AR-NH2
TLN PLN ALN MMP-14 MMP-9(T)
LS4 N.D. 58 ± 4 N.D. N.D. N.D.
RC2 16.2 ± 0.4 22 ± 3 N.D. N.D. N.D.
ML45 N.D. 37 ± 6 N.D. 17 ± 1 N.D.
MT363 7 ± 1 12 ± 4 N.D. 7.2 ± 0.6 6.6 ± 0.4
The Ki values for both bacterial and human metalloproteases were measured
with two different fluorescence quenched substrates, McaPLGL(Dpa)AR-NH2 (for
MMP-9 and MMP-14) and McaRPPGFSAFK(Dnp)-OH (for TLN, PLN and ALN). The
concentration of the substrates used was 4 mM and the highest concentration
of the inhibitor compounds tested was 100 mM. Compounds tested were only
those where 100 mM of the compound reduced the enzymatic activity by 60%
or more. The Ki values are based on 4–6 experiments.
N.D.: not determined.
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and E143, while the other interacted with the side chain of R203 and
N112. In MMP-9 and -14, RC2 bound with the the nitrophenyl group
into the S10-subpocket (Figure 5). In MMP-14, the phosphate groups
were involved in a network of interactions with Zn2þ and E240, back-
bone NH and CO of A200, and the backbone NH groups of L199 and
Y261, in addition to being exposed to solvent. The phosphate groups
of RC2 had fewer strong interactions with the enzyme in the MMPs
than in PLN and TLN, which may contribute to stronger interactions
of RC2 with TLN and PLN than with the MMP-9 and -14.
Except for ALN, MT363 binds quite strong to all enzymes. In
PLN the biphenyl group of MT363 was located within the S2’-sub-
pocket, while one the phosphate groups interacted with Zn2þ,
E141 and the backbone NH of W115, while the other interacted
with N112, F114, in addition to being quite solvent exposed.
However, docking poses with the biphenyl group into the S1-sub-
pocket were also obtained. In TLN, MT363 docked best with the
biphenyl group into the S1-subpocket obtaining stacking interac-
tions with Y157, while also poses with the biphenyl into the S20-
subpocket were obtained. In the best docking pose the phosphate
groups interacted with Zn2þ, R203 and H231, while the other
pointed into the S20-subpocket and interacted with N112 (Figure
5). In the MMPs, the biphenyl moiety was in the S10-subpocket,
while the bisphosphonate group interacted with Zn2þ, the side
chain of E402 (MMP-9 numbering), V398, the backbone of A189,
in addition to being exposed to the solvent.
Conclusion
Several of the tested MMP-inhibitors were identified as strong TLN
and PLN inhibitors, while only BF471 inhbited ALN activity with
more than 60%. Both tested catechol containing compounds and
bisphosphonates bound MMP-9 and 14 with the the phenyl,
biphenyl, chlorophenyl, bromophenyl, nitrophenyl or methoxy-
phenyl ringsystem into the structurally flexible S10-subpocket. In
TLN, PLN and ALN, the contribution of a postively charged argin-
ine (TLN; R203, PLN; R198, ALN; R200) at the entrance of the S10-
subpocket hinders that these functional groups fully enter the S10-
subpocket of the bacterial enzymes. Instead these groups occupy
the S1- or the S20-subpocket, or are located at the entrance of the
S10-subpocket. However, interactions with the arginine seem to be
an important factor for strong binding to the bacterial proteases.
RC2- bound stronger to TLN and PLN than to the MMPs. RC2 may
be used as a scaffold to identify new compounds that bind much
stronger to the bacterial virulence factors TLN and PLN than to







































Figure 5. MT363 and RC2 docked into PLN, TLN MMP-9 (MT363) and MMP-14 (RC2). TLN, PLN and MMP-9. Zinc is shown in dark grey. The side chain of zinc coordi-
nating amino acids are shown in blue. The side chains of some amino acids of importance for ligand binding are displayed with the following colour coding of atoms:
oxygen: red; nitrogen: blue; carbon: yellow; hydrogen: grey. Colour coding of ligand atoms: oxygen: red; sulphur: green; nitrogen: blue; phosphate: orange; hydrogen:
grey; carbon – MT363: purple; carbon – ML32: orange.
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virulence factor inhibitors and represent a new strategy in the
fight against drug resistant bacterial infections.
Experimental section
Materials
TRIS, DMSO, Na2HPO4 and sodium acetate were from Merck
(Darmstadt, Germany). EDTA was from Fluka (Buchs, Switzerland).
Acrylamide, Commassie Brilliant Blue G-250 and Triton X-100 were
from BDH (Poole, UK). RPMI 1640, streptomycin, penicillin, phorbol
12-myristate 13-acetate (PMA), Hepes, Brij-35, Silver nitrate, alka-
line phosphatase-conjugated antibodies and gelatine were pur-
chased from Sigma (St Louis, MO, USA). Gelatine-Sepharose, Q-
Sepharose and Sephadex G-50 (fine) were from GE-Healthcare
(Uppsala, Sweden). DC Protein Assay and unlabelled molecular
weight standards were from BioRad (Richmond, CA, USA). Magic
Marker molecular weight standards were from Invitrogen
(Carlsbad, CA, USA). Western Blotting Luminol reagent and HRP-
conjugated donkey anti-goat secondary antibody were from
Sancta Cruz (Santa Cruz, CA, USA). HRP-conjugated goat anti-rab-
bit secondary antibody was from Southern Biotech (Birmingham,
AL, USA). Foetal bovine serum was from Biochrom AG (Berlin,
Germany). Human MT1-MMP/MMP-14 (catalytic domain), TLN and
PLN were from Calbiochem (San Diego, CA, USA) and Aureolysin
was from BioCentrum Ltd (Krakow, Poland). McaPLGL(Dpa)AR-NH2
(ES001) and McaRPPGFSAFK(Dnp)-OH (ES005) were from R&D
Systems (Minneapolis, MN, USA).
Synthesis of compounds
Synthesis of compounds tested in the present study was reported
previously60,62,63.
Biosynthesis of proMMP-9
The human leukemic monocyte cell-line THP-1 was a kind gift
from Dr. K. Nilsson, Department of Pathology, University of
Uppsala, Sweden. The cells were cultured in RPMI 1640 medium
with 10% foetal bovine serum, 50lg/ml of streptomycin, and
100 units/ml of penicillin. To isolate secreted cell-synthesized
proMMP-9, the cells were washed 3 times in serum-free medium
and then cultured for 72 h in serum-free RPMI 1640 medium with
0.1lM PMA as described previously64,65. Conditioned medium was
harvested, loose cells were pelleted by centrifugation at 1200 rpm
(200 g) for 10min. ProMMP-9 was thereafter isolated and detected
as described below.
Purification and activation of proMMP-9 from the THP-1 cells
The proMMP-9 in conditioned medium from the THP-1 cells was
partly purified as described previously57,65,66. SDS-electrophoresis
under reducing conditions, followed by either silver or Coomassie
Blue staining, showed two bands, a major band at 92 kDa and a
minor band at 28 kDa. Western blotting revealed that the 92 kDa
band was proMMP-9, and the 28 kDa band was TIMP-1. The
amount of proMMP-9 was estimated spectrophotometrically at
280 nm using e280nm¼114,360 M1 cm1 67, ignoring the contribu-
tion of TIMP-1.
The purified proMMP-9 was activated by trypsin, by mixing
approximately 300 mg of proMMP-9 with trypsin (31 lg/ml) for
10min at 37 C in 0.1M Hepes pH 7.5, 0.005% Brij35% and 10mM
CaCl2. The activation and processing of MMP-9 were terminated
by adding a 50 times excess of SBTI (2.7mg/ml) in relation to tryp-
sin and after 10min incubation at room temperature, the mixture
was transferred and kept on ice during the kinetic and inhibition
kinetic measurements. After activation, the activity was deter-
mined with 10 mM of McaPLGL(Dpa)AR-NH2 in 0.1M Hepes pH 7.5,
0.005% Brij35% and 10mM CaCl2 in a total assay volume of
100 mL, at 37 C. Initial rates were measured at an excitation wave-
length of 320 nm and an emission wavelength of 405 nm with a
slit width of 10 nm using a Perkin Elmer LS 50 Luminescence spec-
trometer and the FL WinLab Software Package (Perkin Elmer). The
amount of active MMP-9 was determined by active site titration
using galardin as described previously57.
Expression, purification and activation of recombinant human
proMMP-9 in Sf9 insect cells
The expression and purification of recombinant human full-length
proMMP-9 (rpMMP-9) from Sf9 insect cells were performed as
described previously57. The amount of proMMP-9 was estimated
spectrophotometrically at 280 nm using e280nm¼114,360M1 cm1
57. Activation of the recombinant proMMP-9 was performed with
APMA (auto-activation) as described previously57. The amount of
active MMP-9 was determined by active site titration using galar-
din also described previously57.
Determination of Km values
Km values were determined for McaPLGL(Dpa)AR-NH2 with APMA-
activated recombinant MMP-9 (rMMP-9(A)), trypsin-activated MMP-
9 from THP-1 cells (MMP-9(T)) and MMP-14, and for
McaRPPGFSAFK(Dnp)-OH with ALN, PLN and TLN. Substrate con-
centrations used were 1–10 mM in a total volume of 100 mL of
0.1M Hepes pH 7.5 containing 10mM CaCl2, 0.005% Brij-35 and
1.0% DMSO. Substrate concentrations above 10 mM resulted in
quenching as reported previously58. Initial rate experiments were
performed as described above for the determination of enzyme
activity of MMP-9 during activation and the same excitation and
emission wavelengths were used for both substrates.
Determination of IC50 and Ki values
The various inhibitors were dissolved in 100% DMSO giving an
inhibitor concentration of 10mM. All the inhibitory and control
experiments contained a total and fixed concentration of 1.0%
DMSO. The inhibitory constant IC50 of the various compounds
were performed with inhibitor concentrations ranging from 1010
to 104M in the assay, with a fixed substrate concentration of
4.0 mM in a total volume of 100 mL 0.1M Hepes pH 7.5, 10mM
CaCl2, 0.005% Brij-35 and 1.0% DMSO, except for ALN where the
substrate concentration was 5.0mM. The fixed enzyme concentra-
tion were as follows; 0.28 nM MMP-9(T), 0.05 nM MMP-9(A), 1.0 nM
MMP-14, 1.4 nM ALN, 0.5 nM PLN and 0.21 nM TLN. Enzymes with
and without inhibitors were pre-incubated for 15min at 37 C, the
initial rate assays were started by adding the substrate and the
reaction was followed for 30min. Assays were performed using a
Spectra Max Gemini EM micro-plate reader (Molecular Devices) or
a Clario Star micro plate reader (CLARIOstarVR BMG LABTECH).
Assays were performed at 37 C, using an excitation wavelength
of 320 nm and an emission wavelength of 405 nm with a slit width
of 10 nm. The IC50 values were calculated either in Sigma Plot
(Enzyme kinetics 1.3 module) or in Graph Pad Prism 5 using
Equations (1) or (2) depending on the concentration span of the










where vi is the enzyme activity in the presence of inhibitor, v0 the
activity in the absence of inhibitor, pI¼log [Inhibitor] in M and
pIC50 ¼ log IC50 in M. All experiments were performed in at
least triplicate.
For substrate competitive inhibitors, Equations (3) shows the
relation between IC50 and Ki values based on the fixed concentra-
tion of substrate used and the enzymes Km value for the sub-
strate:
IC50 ¼ Ki ð1þ ½S=KmÞ (3)
Quenching experiments
Some of the catechol and biphosphate derivatives showed a con-
centration dependent fluorescence at wavelengths used for the
McaPLGL(Dpa)AR-NH2 and McaRPPGFSAFK(Dnp)-OH substrates. To
determine to which extent these derivatives could quench the
time dependent enzymatic increase in the fluorescence product of
the processed substrate, quenching experiments were performed
as described previously58. Briefly, the fluorescence (kex¼320 nm,
kem¼405 nm, slit width ¼ 10 nm) of various concentrations of the
fluorescent product of the substrate McaPLGL(Dpa)AR-NH2,
McaPL-OH (0–100 nM), was determined in absence and presence
of various concentrations of the catechol and bisphosphonate
derivatives (0–100 mM). Primary and secondary plots were used to
determine whether the catechol and bisphosphonate derivatives
quenched the McaPL-OH fluorescence.
Docking
The internal Coordinate Mechanics (ICM) program version68 was
used for docking of catechol containing compounds (ML32,
BF471, ML33, BF489, BF486, BF482, BF466, MT336) and bisphosph-
onate containing compounds (RC14, LS4, RC2, MT242, GD16,
ML45, MT363) into the target proteases. The X-ray crystal struc-
tures of PLN (PDB-code:1u4g), TLN (PDB-code: 5dpe), MMP-9 (PDB-
code: 5cuh, ALN (PDB-code: 1bqb) and MMP-14 (PDB-code:1bqq)
were collected from the PDB database and used for docking.
Crystallographic water molecules were removed along with the
co-crystallized small molecule inhibitors. Hydrogen atoms were
added and optimised using the ECEPP/3 force field before the
structures were refined and minimised. The various inhibitors
were built using ICM and minimised before docking. The binding
modes of the inhibitors in the X-ray structure complexes PLN
(1u4g), TLN (5dpe) and MMP-9 (5cuh) were used to define the
binding pocket for docking into these enzymes, using grid maps
that included all amino acids within 5 Å of the cocrystallized inhib-
itors. However, X-ray crystal structures with small molecule inbi-
tors were not available for ALN and MMP-14. For ALN, the X-ray
structure without inhibitor (1bqb) was superimposed with the PLN
complex (1u4g) and the inhibitor in the PLN complex was used to
create docking grids including all amino acids within 5 Å of the
PLN inhibitor. For MMP-14, the X-ray crystal structure of MMP-8
with the inhibitor BF471 (PDB id: 5h8x) was superimposed with
the MMP-14 structure in complex with TIMP-2 (1bqq) and binding
mode of BF471 in MMP-8 was used to create docking grids within
5 Å of BF471. After ceating grid maps, semi-flexible docking was
performed where the enzymes were kept rigid while the ligands
were structurally flexible. Each docking was run in three parallels.
Ligand conformer sampling in vacuo and Monte Carlo global
energy optimisation were used to generate docking poses69, while
the poses were scored using the Virtual Ligand Scoring (VLS) mod-
ule of the ICM program. The VLS scoring function uses steric,
entropic, hydrogen bonding, hydrophobic and electrostatic terms
to calculate the score and also includes a correction term propor-
tional to the number of atoms in the ligand to avoid bias towards
larger ligands70.
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